# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Appln. No.

: 10/767,813

Confirmation No.: 5696

Applicant

: Zhang et al.

Filed

: January 29, 2004

TC/A.U.

: 1614

Examiner

: T. Betton

Customer No.

: 38199

Title

: CYCLOCARBAMATE DERIVATIVES AS PROGESTERONE

RECEPTOR MODULATORS

Mail Stop Amendment Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

## RESPONSE UNDER 35 USC § 121

Sir:

This paper is in timely response to the Office Action dated July 2, 2007 and issued for restriction purposes. Please enter the following elections, amendments, and remarks.

Elections begin on page 2.

Amendments to the Claims begin on page 3.

Remarks/Arguments begin on page 6.

#### **ELECTIONS**

## **Restriction Requirement**

In response to the requirement to elect the claims of Group I or II, Applicants hereby elect the invention of Group II, i.e., a compound. Claims 49-51 read on this election.

## **Species Election**

In response to the requirement to elect one specific compound from claim 49, Applicants hereby elect [3-(4,4-dimethyl-2-oxo-1,4-dihydro-2H-3,1-benzoxazin-6-yl)-5-fluorophenyl]acetonitrile. Claims 49 and 50 read on this election.